RCT Study of Levosimendan Improving Prognosis of Cardiac Arrest

Summary

This study is intended to use a multicenter, double-blind, superior effect, placebo controlled randomized controlled clinical trial to explore the therapeutic effect of Levosimendan (within 6 hours after the recovery of spontaneous circulation) on mortality and multiple organ dysfunction such as heart and brain in patients with cardiac arrest who have recovered from active Cardiopulmonary resuscitation but have low cardiac output syndrome and coma, and the impact of 30-day mortality and neurological function after cardiac arrest.

Timeline

Start

2023-08-01

Primary completion

2024-12-31

Completion

2024-12-31

Drugs

Indications